Ablynx And AbbVie Sign License Agreement For Anti-IL-6R Nanobody - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Ablynx And AbbVie Sign License Agreement For Anti-IL-6R Nanobody



The biopharmaceutical company Ablynx and AbbVie have entered into a license agreement to develop and commercialize the anti-IL-6R Nanobody, ALX-0061, to treat inflammatory diseases.  ALX-0061 is Ablynx's proprietary anti-IL-6R Nanobody that successfully completed a Phase IIA study in February 2013. Nanobodies are Ablynx’s proprietary class of therapeutic proteins based on single-domain antibody fragments. Under the agreement, Ablynx will be responsible for completing Phase II clinical development in rheumatord arthritis and systemic lupus erythematosus. Upon the achievement of predefined success criteria, AbbVie will exercise its right to in-license ALX-0061 and be responsible for subsequent Phase III clinical development and commercialization.  Ablynx will retain an option for copromotion rights in Belgium, the Netherlands, and Luxembourg.  Ablynx will receive an upfront payment of $175 million, which will partly be used to fund the next phases of clinical development of ALX-0061.  Upon achievement of certain development, regulatory, commercial, and sales-based milestones, Ablynx will be eligible to receive additional milestone payments totaling up to $665 million as well as double-digit tiered royalties on net sales upon commercialization.

Source: AbbVie

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here